Titan Pharmaceuticals (TTNP) Competitors $3.67 -0.14 (-3.67%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$4.03 +0.36 (+9.67%) As of 02/21/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends TTNP vs. CING, MTVA, CRVO, PHIO, NERV, TRIB, CLRB, IPA, IMNN, and BCDAShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Cingulate (CING), MetaVia (MTVA), CervoMed (CRVO), Phio Pharmaceuticals (PHIO), Minerva Neurosciences (NERV), Trinity Biotech (TRIB), Cellectar Biosciences (CLRB), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Cingulate MetaVia CervoMed Phio Pharmaceuticals Minerva Neurosciences Trinity Biotech Cellectar Biosciences ImmunoPrecise Antibodies Imunon BioCardia Titan Pharmaceuticals (NASDAQ:TTNP) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Which has more volatility & risk, TTNP or CING? Titan Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500. Is TTNP or CING more profitable? Titan Pharmaceuticals' return on equity of -118.01% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -118.01% -103.79% Cingulate N/A -570.20%-236.15% Does the MarketBeat Community prefer TTNP or CING? Titan Pharmaceuticals received 325 more outperform votes than Cingulate when rated by MarketBeat users. However, 76.92% of users gave Cingulate an outperform vote while only 53.77% of users gave Titan Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTitan PharmaceuticalsOutperform Votes33553.77% Underperform Votes28846.23% CingulateOutperform Votes1076.92% Underperform Votes323.08% Do analysts rate TTNP or CING? Cingulate has a consensus price target of $16.00, suggesting a potential upside of 269.94%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Titan Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher earnings and valuation, TTNP or CING? Titan Pharmaceuticals has higher revenue and earnings than Cingulate. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan Pharmaceuticals$180K18.55-$5.57MN/AN/ACingulateN/AN/A-$23.53MN/AN/A Does the media prefer TTNP or CING? In the previous week, Titan Pharmaceuticals' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score. Company Overall Sentiment Titan Pharmaceuticals Neutral Cingulate Neutral Do insiders & institutionals believe in TTNP or CING? 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTitan Pharmaceuticals beats Cingulate on 7 of the 13 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48M$3.12B$5.82B$9.09BDividend YieldN/A1.57%4.77%3.84%P/E RatioN/A14.9418.9215.38Price / Sales18.55361.02453.2984.08Price / CashN/A177.4343.8437.22Price / Book0.423.687.644.65Net Income-$5.57M-$71.72M$3.18B$245.69M7 Day Performance-8.93%-2.46%-1.95%-2.67%1 Month Performance7.94%-0.25%-0.23%-2.16%1 Year Performance-53.60%-12.31%16.69%12.90% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.3829 of 5 stars$3.67-3.7%N/A-51.9%$3.48M$180,000.000.0010Analyst ForecastGap DownCINGCingulate2.8604 of 5 stars$4.51+3.9%$16.00+254.8%+300.5%$14.49MN/A0.0020MTVAMetaVia1.6222 of 5 stars$1.67+1.5%$12.00+616.8%N/A$14.43MN/A0.0010Gap UpCRVOCervoMed3.5982 of 5 stars$2.33+6.4%$40.86+1,653.5%-84.3%$14.38M$7.14M0.004Analyst UpgradeNews CoveragePHIOPhio Pharmaceuticals3.3556 of 5 starsN/A$36.00+∞-75.3%$13.98MN/A0.0010Analyst ForecastAnalyst RevisionNews CoverageNERVMinerva Neurosciences3.2149 of 5 stars$1.97-3.9%$5.00+153.8%-79.3%$13.77MN/A-4.489Analyst ForecastNews CoverageTRIBTrinity Biotech0.4042 of 5 stars$0.76flatN/AN/A$13.72M$56.83M-0.34480CLRBCellectar Biosciences1.979 of 5 stars$0.29+3.5%$17.67+5,975.2%-90.4%$13.40MN/A-0.1710Analyst ForecastIPAImmunoPrecise Antibodies2.9808 of 5 stars$0.42-5.0%$5.00+1,085.4%-77.6%$13.10M$18.16M-0.5480News CoverageIMNNImunon2.3242 of 5 stars$0.90flat$20.50+2,177.8%+70.2%$13.05M$500,000.00-0.4830Analyst ForecastNews CoverageGap UpBCDABioCardia2.7993 of 5 stars$2.84+4.4%$25.00+780.3%-63.6%$13.01M$480,000.00-0.6840Gap Down Related Companies and Tools Related Companies Cingulate Alternatives MetaVia Alternatives CervoMed Alternatives Phio Pharmaceuticals Alternatives Minerva Neurosciences Alternatives Trinity Biotech Alternatives Cellectar Biosciences Alternatives ImmunoPrecise Antibodies Alternatives Imunon Alternatives BioCardia Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TTNP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
